Qilu Pharmaceutical Co., Ltd.
Clinical trials sponsored by Qilu Pharmaceutical Co., Ltd., explained in plain language.
-
Experimental drug duo targets Tough-to-Treat cancers
Disease control Recruiting nowThis study is testing whether two new drugs, QLP2117 and QL2107, are safe and effective when given together to patients with advanced solid tumors that have stopped responding to standard treatments. Researchers will enroll 90 patients to find the right dose and see if the combin…
Phase: PHASE1, PHASE2 • Sponsor: Qilu Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Apr 01, 2026 21:26 UTC
-
New drug trial aims to shrink tumors before colon cancer surgery
Disease control Recruiting nowThis study is testing whether a new immunotherapy drug called QL1706, given before surgery, works better than standard treatments for a specific type of colon cancer. It will involve 363 adults with a genetic feature in their tumor (MSI-H/dMMR) that makes it more likely to respon…
Phase: PHASE3 • Sponsor: Qilu Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Apr 01, 2026 14:41 UTC
-
New hope for Tough-to-Treat blood cancer: experimental drug enters final testing
Disease control Recruiting nowThis study is testing a new drug called QLS32015 for people with multiple myeloma that has come back or stopped responding to other treatments. It will compare the new drug against two standard treatment combinations to see which is better at controlling the cancer and is safer. …
Phase: PHASE3 • Sponsor: Qilu Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Mar 31, 2026 12:11 UTC
-
New hope for advanced breast cancer patients as novel drug combo enters clinical testing
Disease control Recruiting nowThis study is testing a new drug called QLS1304 in combination with standard hormone therapy for people with advanced ER+/HER2- breast cancer that has stopped responding to previous hormone treatments. The trial aims to find the safest and most effective dose and see if the combi…
Phase: PHASE1, PHASE2 • Sponsor: Qilu Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Mar 30, 2026 14:33 UTC
-
Major trial tests promising new treatment for aggressive breast cancer
Disease control Recruiting nowThis study is testing whether a new drug called ESG401 works better than standard chemotherapy for people with advanced triple-negative breast cancer that has spread or returned. The trial will involve 504 participants who haven't had previous treatment for their advanced cancer.…
Phase: PHASE3 • Sponsor: Qilu Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Mar 30, 2026 14:33 UTC
-
New hope for Tough-to-Treat blood cancer
Disease control Recruiting nowThis study is testing whether a new drug called QLS32015 works better when combined with other existing myeloma drugs. It is for people whose multiple myeloma has come back or is no longer responding to their current treatments. The main goals are to see if the combinations can s…
Phase: PHASE2 • Sponsor: Qilu Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Mar 30, 2026 14:31 UTC
-
Race for better antibiotics: new combo battles deadly hospital pneumonia
Disease control Recruiting nowThis study is testing if a new combination of antibiotics (meropenem + pralubactam) works as well as an existing treatment for severe pneumonia that patients get in the hospital or while on a ventilator. It will involve about 420 adult patients. The main goal is to see if the new…
Phase: PHASE3 • Sponsor: Qilu Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Mar 30, 2026 14:29 UTC
-
New hope for tough pancreatic cancer: major trial tests drug combo
Disease control Recruiting nowThis study is testing if adding a new drug called QLS31905 to standard chemotherapy works better than chemotherapy alone for adults with advanced pancreatic cancer that has a specific marker (CLDN18.2). It will involve about 602 people who have not yet received treatment for thei…
Phase: PHASE3 • Sponsor: Qilu Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Mar 27, 2026 12:38 UTC
-
New weapon against advanced cancers enters human testing
Disease control Recruiting nowThis study is testing a new drug called QLC5508, given with other cancer medicines, for people with advanced solid tumors. The main goals are to find the safest and most effective dose and to see if the combination can shrink tumors. It will enroll about 444 adults in China who h…
Phase: PHASE1, PHASE2 • Sponsor: Qilu Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Mar 23, 2026 15:19 UTC
-
New cancer drug begins first human testing
Disease control Recruiting nowThis is the first study in people to test a new cancer drug called QLS-1304. It aims to find a safe dose and check for side effects in 180 adults with advanced solid tumors that have not responded to standard treatments. The main goal is to determine how much of the drug the body…
Phase: PHASE1 • Sponsor: Qilu Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Mar 20, 2026 14:48 UTC
-
New pill aims to tame debilitating heavy periods
Disease control Recruiting nowThis study is testing whether a daily pill called relugolix can safely reduce heavy menstrual bleeding in women who have uterine fibroids. About 120 participants will take either the real pill or a placebo (a dummy pill) for 12 weeks to see which one works better. The main goal i…
Phase: PHASE3 • Sponsor: Qilu Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Mar 20, 2026 14:48 UTC
-
New drug trial offers hope for Tough-to-Treat blood cancers
Disease control Recruiting nowThis study is testing a new drug called QLS2309 for adults with advanced blood cancers that have returned or stopped responding to other treatments. The main goals are to find a safe dose and see how the body handles the drug. Researchers will also look for early signs that the d…
Phase: PHASE1 • Sponsor: Qilu Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Mar 17, 2026 13:09 UTC
-
New drug aims to rescue cancer patients from chemotherapy side effect
Disease control Recruiting nowThis study is testing if an investigational drug called QL0911 can safely and effectively raise platelet counts in cancer patients. Low platelets, a common and serious side effect of chemotherapy, can force treatment delays. The goal is to help patients complete their planned can…
Phase: PHASE2, PHASE3 • Sponsor: Qilu Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Mar 11, 2026 14:53 UTC
-
Scientists test how new antibiotic reaches human lungs
Knowledge-focused Recruiting nowThis early-stage study aims to understand how a new antibiotic combination reaches different parts of the lungs in healthy adults. Researchers will measure drug levels in blood, lung fluid, and immune cells after intravenous administration. The study involves 16 healthy Chinese p…
Phase: PHASE1 • Sponsor: Qilu Pharmaceutical Co., Ltd. • Aim: Knowledge-focused
Last updated Apr 01, 2026 14:42 UTC